These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19467222)

  • 1. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
    Grunt TW; Wagner R; Grusch M; Berger W; Singer CF; Marian B; Zielinski CC; Lupu R
    Biochem Biophys Res Commun; 2009 Jul; 385(3):454-9. PubMed ID: 19467222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
    Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
    Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
    Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
    Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
    Kim KK; Lee JJ; Yang Y; You KH; Lee JH
    Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
    Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
    Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.
    Li N; Bu X; Tian X; Wu P; Yang L; Huang P
    Nutr Cancer; 2012 Aug; 64(6):864-70. PubMed ID: 22860766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SDF-1alpha/CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element-binding protein-1 activation in cancer cells.
    Kim K; Kim HY; Cho HK; Kim KH; Cheong J
    Carcinogenesis; 2010 Apr; 31(4):679-86. PubMed ID: 20067991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.
    Scoles DR; Pavelka J; Cass I; Tran H; Baldwin RL; Armstrong K; Karlan BY
    Gynecol Oncol; 2007 Jan; 104(1):120-8. PubMed ID: 16956650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New synthetic inhibitors of fatty acid synthase with anticancer activity.
    Turrado C; Puig T; García-Cárceles J; Artola M; Benhamú B; Ortega-Gutiérrez S; Relat J; Oliveras G; Blancafort A; Haro D; Marrero PF; Colomer R; López-Rodríguez ML
    J Med Chem; 2012 Jun; 55(11):5013-23. PubMed ID: 22559865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway.
    Lin VC; Chou CH; Lin YC; Lin JN; Yu CC; Tang CH; Lin HY; Way TD
    J Agric Food Chem; 2010 Apr; 58(8):4786-93. PubMed ID: 20218616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.